Interim results from Mediclinic show that minority shareholders are probably getting a fair deal from the Remgro-led consortium that made an offer of £5.04 per share for their shares. Based on the latest results, the offer equates to a price-earnings ratio of 22 times, while shareholders are bound to appreciate the advantages of having a bird in the hand rather than seeing them flying around the bush.
The scheme of arrangement has received approval from all the relevant authorities in different countries, except in SA – the only uncertainty remaining for shareholders.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: